Index Entries

Sanaz Rezaeian, Fatemeh Rahmanian, Zohre Rajabpour, Ali Taghipour, Mirza Ali Mofazzal Jahromi, Abdolvahab Rahmanian, Heshmatollah Shakeri, Navid Kalani, Maryam Jalali Jahromi, and Amir Abdoli
March 30, 2024
Heliyon
Jahrom University of Medical Sciences (Iran)

"Case presentation: A 63-year-old woman came to the emergency department with generalized headache, fatigue, and myalgia. The record of the history revealed that the patient received the first dose of Sinopharm/BBIBPCorV COVID-19 vaccine four days before admission ...

The patient was examined by a dermatologist and the diagnosis of herpes zoster was confirmed. Due to the worsening of symptoms, especially persistent headache, nausea, and vomiting, brain computed tomography (CT) and neurology consultation were performed. Brain CT showed hypodensity in the cerebellum. Neurological consultation recommended brain magnetic resonance imaging (MRI). Hence, a brain MRI with and without gadolinium was performed. Extensive signal changes in the cortex and cerebellum were reported in MRI, as well as necrotizing lesions, suggesting the diagnosis of encephalitis ... Subsequently, she was transferred to the ICU (Peymaniyeh hospital, Jahrom, Iran) for further evaluation with the preliminary diagnosis of encephalitis. In the ICU, the patient's delirium worsened and the patient's consciousness occasionally decreased ... After 33 days of hospitalization and receiving 28 days of acyclovir (Supplementary Table 1), the patient was discharged from the hospital in good general condition."

document
adverse events,clinical cases,COVID-19,hospitalizations,neurological disorders,shingles (herpes zoster) and chickenpox (herpes varicella),vaccines